Posted by Michael Wonder on 07 Dec 2021
China clears insurance coverage for Kainos Medicine’s HIV drug
6 December 2021 - A home-grown HIV treatment developed by Kainos Medicine and out-licensed to China’s Jiangsu Aidea Pharmaceuticals has been cleared for insurance coverage by Chinese health authorities.
Korean clinical-stage biotech company Kainos Medicine announced Monday that Chinese health authorities have approved listing of its HIV drug Ainuovirine licensed out to Jiangsu Aidea Pharmaceuticals in China’s medical insurance reimbursement scheme.
The approval comes less than six months after the drug was cleared for marketing as the first oral HIV treatment commercialized in China.
